Gyre Therapeutics, Inc. Accounts and Other Receivables, Net, Current
Gyre Therapeutics, Inc. (GYRE) had Accounts and Other Receivables, Net, Current of $5.00 million as of 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Balance Sheet › Assets › Assets, Current › Receivables, Net, Current
us-gaap:AccountsAndOtherReceivablesNetCurrent · last filed 2023-10-26
- 2023-03-31: Accounts and Other Receivables, Net, Current $5.00M.
- 2022-12-31: Accounts and Other Receivables, Net, Current $5.00M.
- 2022-09-30: Accounts and Other Receivables, Net, Current $5.00M.
- 2022-06-30: Accounts and Other Receivables, Net, Current $5.00M.
| Period end | Accounts and Other Receivables, Net, Current |
|---|---|
| 2023-03-31 | $5.00M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $5.00M 10-Q · filed 2023-10-26 |
| 2022-09-30 | $5.00M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $5.00M 10-Q · filed 2022-08-15 |
| 2021-12-31 | $1.82M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |